# Phase 4 Depressive Disorder, Major trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 4 for Depressive Disorder, Major that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 Depressive Disorder, Major trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/depressive-disorder-major

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 29, 2026 | NCT07555743 | Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia | Institut d'Investigació Biomèdica de Bellvitge | Phase 4 | Not yet recruiting | Insomnia, Major Depressive Disorder | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555743) |
| August 24, 2025 | NCT07139106 | Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | New York State Psychiatric Institute | Phase 4 | Not yet recruiting | Major Depressive Disorder (MDD) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139106) |
| August 22, 2025 | NCT07136714 | Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity | Nordsjaellands Hospital | Phase 4 | Recruiting | Major Depressive Disorder | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136714) |
| August 8, 2025 | NCT07110831 | Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria | University of Ibadan | Phase 4 | Not yet recruiting | Depression, HIV | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07110831) |
| August 5, 2025 | NCT07105111 | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While... | Neurocrine Biosciences | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105111) |
| July 22, 2025 | NCT07076342 | The Role of mGluR5 in CBT-I | Stony Brook University | Phase 4 | Recruiting | Major Depressive Disorder (MDD) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076342) |
| June 10, 2025 | NCT07011693 | Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I) | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Major Depressive Disorder (MDD) | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011693) |
| December 27, 2024 | NCT06749470 | A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules | Central South University | Phase 4 | Not yet recruiting | Major Depressive Disorder (MDD) | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06749470) |
| November 21, 2024 | NCT06699966 | Stony Brook Medicine Anti-Inflammatory Trial | Stony Brook University | Phase 4 | Not yet recruiting | Major Depressive Disorder | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06699966) |
| November 5, 2024 | NCT06675851 | Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People | Medical University of Vienna | Phase 4 | Recruiting | Major Depressive Disorder (MDD) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06675851) |
| October 16, 2024 | NCT06644833 | Effective of Transcranial Magnetic Stimulation (TMS) vs Treatment as Usual for First-Episode Depression in Adults | Sultan Qaboos University | Phase 4 | Not yet recruiting | Major Depressive Disorder | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06644833) |
| September 24, 2024 | NCT06610305 | Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression | University of North Carolina, Chapel Hill | Phase 4 | Recruiting | Major Depressive Disorder | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06610305) |
| May 23, 2024 | NCT06426485 | To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets | Luye Pharma Group Ltd. | Phase 4 | Not yet recruiting | Major Depressive Disorder | 736 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06426485) |
| May 16, 2024 | NCT06417437 | Non-invasive BCI and Application Verification for Depressed People | Shanghai Mental Health Center | Phase 4 | Recruiting | Depression, Major Depressive Disorder, Bipolar Depression | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06417437) |
| March 12, 2024 | NCT06303076 | Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial | Sultan Qaboos University | Phase 4 | Not yet recruiting | Depressive Disorder, Major | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06303076) |
| January 25, 2024 | NCT06223880 | A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Axsome Therapeutics, Inc. | Phase 4 | Recruiting | Major Depressive Disorder | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06223880) |
| October 27, 2023 | NCT06103760 | Positioning of Esketamine Treatment in the Real-world Management of Depression | Royal North Shore Hospital | Phase 4 | Recruiting | Major Depressive Disorder | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06103760) |
| July 6, 2023 | NCT05933538 | Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder | Sultan Qaboos University | Phase 4 | Not yet recruiting | Depressive Disorder, Major | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05933538) |
| June 7, 2023 | NCT05892744 | Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression | University of Texas at Austin | Phase 4 | Recruiting | Major Depressive Disorder, Chronic Major Depression, Recurrent | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05892744) |
| July 8, 2022 | NCT05450432 | Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | Massachusetts General Hospital | Phase 4 | Recruiting | Major Depressive Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05450432) |
| August 23, 2021 | NCT05017311 | Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D) | Nova Scotia Health Authority | Phase 4 | Recruiting | Major Depressive Disorder | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05017311) |
| August 13, 2021 | NCT05004987 | Aβ Dynamics in LLMD | NYU Langone Health | Phase 4 | Recruiting | Alzheimer Disease, Major Depressive Disorder | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05004987) |
| August 15, 2019 | NCT04057378 | Optimal Electrical Stimulus During Electroconvulsive Therapy | Region Örebro County | Phase 4 | Recruiting | Depressive Disorder, Major, Depression, Bipolar | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04057378) |
| April 27, 2016 | NCT02752542 | Personalized Indications for CBT and Antidepressants in Treating Depression | Nova Scotia Health Authority | Phase 4 | Recruiting | Major Depressive Disorder, Persistent Depressive Disorder | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02752542) |
| May 2, 2014 | NCT02129751 | Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder | Bausch Health Americas, Inc. | Phase 4 | Not yet recruiting | Major Depressive Disorder | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02129751) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sultan Qaboos University | 3 |
| Stony Brook University | 2 |
| Nova Scotia Health Authority | 2 |
| [Axsome Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/axsome-therapeutics-inc) | 1 |
| University of Ibadan | 1 |
| Medical University of Vienna | 1 |
| Shanghai Mental Health Center | 1 |
| NYU Langone Health | 1 |
| Central South University | 1 |
| [Bausch Health Americas, Inc.](https://specstream.ai/data/clinical-trials/company/bausch-health-americas-inc) | 1 |
| Royal North Shore Hospital | 1 |
| New York State Psychiatric Institute | 1 |
| Massachusetts General Hospital | 1 |
| [Luye Pharma Group Ltd.](https://specstream.ai/data/clinical-trials/company/luye-pharma-group-ltd) | 1 |
| Region Örebro County | 1 |
| Institut d'Investigació Biomèdica de Bellvitge | 1 |
| Nordsjaellands Hospital | 1 |
| University of Texas at Austin | 1 |
| University of North Carolina, Chapel Hill | 1 |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 8 |
| China | 2 |
| Canada | 2 |
| Nigeria | 1 |
| Austria | 1 |
| Australia | 1 |
| Sweden | 1 |
| Spain | 1 |
| Denmark | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Real estate investment firms in the United States](https://specstream.ai/data/businesses/real-estate-investment-firms/united-states)
- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
- [Dental supply stores in the United States](https://specstream.ai/data/businesses/dental-supply-stores/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [Puerto Rican restaurants in the United States](https://specstream.ai/data/businesses/puerto-rican-restaurants/united-states)
- [Aircraft manufacturers in the United States](https://specstream.ai/data/businesses/aircraft-manufacturers/united-states)
